These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 33593653)

  • 1. Reply to Claudia Signorini and Massimo Maffezzini's Letter to the Editor re: Maria S. Lindgren, Peter Bue, Nessn Azawi, et al. The DaBlaCa-13 Study: Short-term, Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in Non-muscle-invasive Bladder Cancer-A Randomized Controlled Trial. Eur Urol 2020;78:856-62.
    Lindgren MS; Jensen JB
    Eur Urol; 2021 May; 79(5):e137. PubMed ID: 33593653
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Maria S. Lindgren, Peter Bue, Nessn Azawi, et al. The DaBlaCa-13 Study: Short-term, Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in Non-muscle-invasive Bladder Cancer-A Randomized Controlled Trial. Eur Urol 2020;78:856-62.
    Signorini C; Maffezzini M
    Eur Urol; 2021 May; 79(5):e135-e136. PubMed ID: 33593654
    [No Abstract]   [Full Text] [Related]  

  • 3. Reply to Benjamin Pradere, Giuseppe Basile, and Thomas Seisen's Letter to the Editor re: Maria S. Lindgren, Eric Hansen, Nessn Azawi, Anna M. Nielsen, Lars Dyrskjøt, Jørgen B. Jensen. DaBlaCa-13 Study: Oncological Outcome of Short-term, Intensive Chemoresection with Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial. J Clin Oncol 2023;41:2,206-11.
    Lindgren MS; Jensen JB
    Eur Urol; 2023 Apr; 83(4):e107-e108. PubMed ID: 36710202
    [No Abstract]   [Full Text] [Related]  

  • 4. Re: Maria S. Lindgren, Eric Hansen, Nessn Azawi, Anna M. Nielsen, Lars Dyrskjøt, Jørgen B. Jensen. DaBlaCa-13 Study: Oncological Outcome of Short-term, Intensive Chemoresection with Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial. J Clin Oncol. In press. https://doi.org/10.1200/JCO.22.00470.
    Pradere B; Basile G; Seisen T
    Eur Urol; 2023 Apr; 83(4):e105-e106. PubMed ID: 36717285
    [No Abstract]   [Full Text] [Related]  

  • 5. The DaBlaCa-13 Study: Short-term, Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in Non-muscle-invasive Bladder Cancer-A Randomised Controlled Trial.
    Lindgren MS; Bue P; Azawi N; Blichert-Refsgaard L; Sundelin MO; Dyrskjøt L; Jensen JB
    Eur Urol; 2020 Dec; 78(6):856-862. PubMed ID: 32736928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reply to Harshit Garg, Brusabhanu Nayak and Prabhjot Singh's Letter to the Editor Re: Tom J.H. Arends, Ofer Nativ, Massimo Maffezzini, et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guerin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer. Eur Urol 2016;69:1046-52.
    Arends TJH; Witjes JA
    Eur Urol; 2019 Feb; 75(2):e26. PubMed ID: 30268661
    [No Abstract]   [Full Text] [Related]  

  • 7. Reply to Sławomir Poletajew, Piotr Radziszewski, Juan Palou's Letter to the Editor re: Tom J.H. Arends, Ofer Nativ, Massimo Maffezzini, et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer. Eur Urol 2016;69:1046-52.
    Arends TJ; Witjes JA
    Eur Urol; 2017 Jan; 71(1):e31-e32. PubMed ID: 27425383
    [No Abstract]   [Full Text] [Related]  

  • 8. Re: Tom J.H. Arends, Ofer Nativ, Massimo Maffezzini, et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guerin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer. Eur Urol 2016;69:1046-52.
    Garg H; Nayak B; Singh P
    Eur Urol; 2019 Feb; 75(2):e25. PubMed ID: 30237025
    [No Abstract]   [Full Text] [Related]  

  • 9. Re: Tom J.H. Arends, Ofer Nativ, Massimo Maffezzini, et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer. Eur Urol 2016;69:1046-52.
    Poletajew S; Radziszewski P; Palou J
    Eur Urol; 2017 Jan; 71(1):e29-e30. PubMed ID: 27417035
    [No Abstract]   [Full Text] [Related]  

  • 10. Re: DaBlaCa-13 Study: Oncological Outcome of Short-term, Intensive Chemoresection with Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial.
    Laukhtina E; Shariat SF
    Eur Urol; 2023 Nov; 84(5):512-513. PubMed ID: 37270391
    [No Abstract]   [Full Text] [Related]  

  • 11. Reply to Fabio Campodonico, Francesca Mattioli, and Carlo Introini's Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003.
    Tan WS; Kelly JD;
    Eur Urol; 2023 Jan; 83(1):e29-e30. PubMed ID: 36272948
    [No Abstract]   [Full Text] [Related]  

  • 12. Reply to Suman Sahoo, Abhishek Pandy, Swarnendu Mandal, Manoj Kumar Das, and Prasant Nayak's Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003.
    Tan WS; Mustard C; Kelly JD;
    Eur Urol; 2023 Feb; 83(2):e48-e49. PubMed ID: 36456403
    [No Abstract]   [Full Text] [Related]  

  • 13. Re: Per-Uno Malmström, Richard J. Sylvester, David E. Crawford, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol 2009;56:247-56.
    Aldemir M; Canda AE; Balbay MD
    Eur Urol; 2010 Aug; 58(2):e23; author reply e24-5. PubMed ID: 20542629
    [No Abstract]   [Full Text] [Related]  

  • 14. Re: Wei Shen Tan, Aaron Prendergast, Charlotte Ackermann, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003.
    Campodonico F; Mattioli F; Introini C
    Eur Urol; 2023 Feb; 83(2):e56-e57. PubMed ID: 36372625
    [No Abstract]   [Full Text] [Related]  

  • 15. Re: Wei Shen Tan, Aaron Prendergast, Charlotte Ackerman, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003.
    Sahoo S; Pandey A; Mandal S; Kumar Das M; Nayak P
    Eur Urol; 2023 Feb; 83(2):e47. PubMed ID: 36404203
    [No Abstract]   [Full Text] [Related]  

  • 16. Re: Per-Uno Malmström, Richard J. Sylvester, David E. Crawford, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol 2009;56:247-56.
    Lamm D; Böhle A; Palou J; Persad R; Brausi M; Colombel M; Akaza H; Buckley R
    Eur Urol; 2010 Feb; 57(2):e7-9; author reply e10-1. PubMed ID: 19914768
    [No Abstract]   [Full Text] [Related]  

  • 17. Reply to Manish Garg, Apul Goel and Jai Prakash's letter to the editor re: Renzo Colombo, Lorenzo Rocchini, Nazareno Suardi, et al. Neoadjuvant short-term intensive intravesical mitomycin C regimen compared with weekly schedule for low-grade recurrent non-muscle-invasive bladder cancer: preliminary results of a randomised phase 2 study. Eur Urol 2012;62:797-802.
    Colombo R; Rocchini L; Suardi N; Benigni F; Colciago G; Bettiga A; Pellucchi F; Maccagnano C; Briganti A; Salonia A; Rigatti P; Montorsi F
    Eur Urol; 2013 Jan; 63(1):e7-8. PubMed ID: 23092542
    [No Abstract]   [Full Text] [Related]  

  • 18. Re: Willem Oosterlinck, Ziya Kirkali,Richard Sylvester, et al. Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTCGenito-urinary Group Randomized Phase 2 Trial (30993). Eur Urol 2011;59:438-46.
    Ooi WL; Stockler M; Hayne D
    Eur Urol; 2011 Jul; 60(1):e1; author reply e2-3. PubMed ID: 21489685
    [No Abstract]   [Full Text] [Related]  

  • 19. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
    Arends TJ; Nativ O; Maffezzini M; de Cobelli O; Canepa G; Verweij F; Moskovitz B; van der Heijden AG; Witjes JA
    Eur Urol; 2016 Jun; 69(6):1046-52. PubMed ID: 26803476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reasons for intravesical instillation postponement during adjuvant treatment of non-muscle-invasive bladder cancer: A prospective study.
    Khan W; Zugail AS; Blanc E; Neuziller Y; Lebret T
    Prog Urol; 2020 Feb; 30(2):75-79. PubMed ID: 31953014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.